Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Jacqueline Cloos, PhD, Godefridus J Peters, PhD, Marjon Al, BSc, Yehuda G Assaraf, PhD, Lixia Wang, PhD, Jack W. Singer, MD, Jorge E. Cortes, MD, Gert J. Ossenkoppele, MD PhD, Gerrit Jansen, PhD

Blood (2018) 132 (Supplement 1): 3945.

https://doi.org/10.1182/blood-2018-99-114447

Published: 2018

Journal Articles

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Vishnu Mishra, PhD, Matthew R Janes, PhD, Linda Kessler, BA

Blood (2018) 132 (Supplement 1): 5349.

https://doi.org/10.1182/blood-2018-99-116969

Published: 2018

Journal Articles

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Ruth Alonso Alonso, PhD, Rufino Mondejar García, PhD, Jose Pedro Vaqué Díez, PhD, Nuria García Díaz, PhDcandidate, Cristina Pérez Menéndez, PhD, Francis Burrows, PhD, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD, Miguel A. Piris, PhD MD

Blood (2018) 132 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2018-99-118291

Published: 2018

Journal Articles

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Diego Coutinho, BS, Abdullah Mahmood Ali, PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Karen Bracken, MHS, Joseph G. Jurcic, MD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 1677.

https://doi.org/10.1182/blood.V130.Suppl_1.1677.1677

Published: 2017

Journal Articles

Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Victoria X Wang, Elisabeth Paietta, PhD, Rhett P. Ketterling, MD, Witold Rybka, MD, Hillard M. Lazarus, MD, Mark R Litzow, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Frederick R Appelbaum, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1308.

https://doi.org/10.1182/blood.V126.23.1308.1308

Published: 2015

Journal Articles

Glutathionylation of NF-Kb and Procaspase-3 Regulates Inducible Nitric Oxide Synthase Expression and Apoptosis of Chronic Myeloid Leukemia Cells

Abhishek Singh, Megha Dubey, Deepika Awasthi, Sheela Nagaroti, Manoj Barthwal, Rabindra Jena, MD, Anil K Tripathi, MD, Madhu Dikshit

Blood (2014) 124 (21): 3131.

https://doi.org/10.1182/blood.V124.21.3131.3131

Published: 2014

Journal Articles

R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Selina Luger, MD, Lynette Zickl, MS, Elisabeth Paietta, PhD, Rhett P Ketterling, MD, Hillard M Lazarus, MD, Witold Rybka, MD, Mark R Litzow, MD, Jacob M Rowe, MD, Richard A. Larson, MD, Martin S. Tallman, MD

Blood (2012) 120 (21): 676.

https://doi.org/10.1182/blood.V120.21.676.676

Published: 2012

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

Manumycin Induces Apoptosis of Leukemic Stem Cells Through Down-Regulation of Bcl2

Miaorong She, Jinggao Li, Xilin Chen, Xin Du, PhD, Wei Lin, Zesheng Lu, Yanjie He, Kunyuan Guo

Blood (2011) 118 (21): 4738.

https://doi.org/10.1182/blood.V118.21.4738.4738

Published: 2011

Journal Articles

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Dominika Nowis, MD, PhD, Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Angelika Muchowicz, MSc, Malgorzata Wanczyk, MSc, Eliza Glodkowska-Mrowka, MD, Kamil Bojarczuk, BSc, Malgorzata Firczuk, PhD, Ewa Wilczek, PhD, Malgorzata Wachowska, MSc, Justyna Chlebowska, MSc, Michal Dwojak, Marta Miaczynska, PhD, Tomasz Stoklosa, MD, PhD, Jakub Golab, MD, PhD

Blood (2011) 118 (21): 3722.

https://doi.org/10.1182/blood.V118.21.3722.3722

Published: 2011

Journal Articles

Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells

Michael A Morgan, PhD, Fredrick O Onono, Peter H Spielmann, Thangaiah Subramanian, Michaela Scherr, Letizia Venturinin, Iris Dallmann, Arnold Ganser, MD, Christoph W.M. Reuter

Blood (2011) 118 (21): 1418.

https://doi.org/10.1182/blood.V118.21.1418.1418

Published: 2011

Journal Articles

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig, Scott H. Kaufmann

Blood (2011) 118 (18): 4872–4881.

https://doi.org/10.1182/blood-2011-02-334870

Published: 2011

Includes: Supplemental data

Journal Articles

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Blood (2011) 118 (18): 4882–4889.

https://doi.org/10.1182/blood-2011-02-334904

Published: 2011

Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD

Blood (2010) 116 (21): 3315.

https://doi.org/10.1182/blood.V116.21.3315.3315

Published: 2010

Journal Articles

DNA damage-induced Leukaemic Stem and Progenitor Cell Kill with Mylotarg and Tipifarnib/Zarnestra Drug Combination In Acute Myeloid Leukemia (AML)

Mays Jawad, PhD, Ning Yu, Nigel H. Russell, MD, Monica Pallis, PhD

Blood (2010) 116 (21): 1824.

https://doi.org/10.1182/blood.V116.21.1824.1824

Published: 2010

Journal Articles

BMS-214662 Eliminates Quiescent and Proliferating Acute Myeloid Leukemia Cells through Activation of Protein Kinase Cβ and Enhances the Efficacy of Cytosine Arabinoside

Francesca Pellicano, PhD, Amy Sinclair, BSc, MSc, Alan Hair, BSc, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Mhairi Copland, PhD, BSc, MRCP, FRCPath

Blood (2010) 116 (21): 2167.

https://doi.org/10.1182/blood.V116.21.2167.2167

Published: 2010

Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Blood (2010) 116 (21): 287.

https://doi.org/10.1182/blood.V116.21.287.287

Published: 2010

Journal Articles

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Mitch Raponi, PhD, Tatiana Vener, PhD, Carlo Derecho, MSc, Jacqueline Greer, RN, BSN, Sami Malek, MD, John Palma, PhD, Judith E Karp, MD

Blood (2009) 114 (22): 4154.

https://doi.org/10.1182/blood.V114.22.4154.4154

Published: 2009

Journal Articles

Increase of Sensitivity to Chemotherapy and NK-Mediated Cytotoxicity of Leukemic Stem Cell by a Farnesyltransferase Inhibitor.

Miaorong She, MD, Jinggao Li, Xilin Chen, Xingqing Niu, Kunyuan Guo, Xin Du, Maohua Zhou, MD, Yanjie He, Yi Le

Blood (2009) 114 (22): 4161.

https://doi.org/10.1182/blood.V114.22.4161.4161

Published: 2009

NARROW

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells

Crosstalk between the IGF1 and CXCL12 Pathways Defines Objective Responses to the Farnesyl Transferase Inhibitor Tipifarnib in AML and PTCL Patients

Identification of Tipifarnib Sensitivity Biomarkers in T-Cell Tumor Cell Lines

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902

Glutathionylation of NF-Kb and Procaspase-3 Regulates Inducible Nitric Oxide Synthase Expression and Apoptosis of Chronic Myeloid Leukemia Cells

R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Manumycin Induces Apoptosis of Leukemic Stem Cells Through Down-Regulation of Bcl2

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Modulation of Anthracycline-Induced Cytotoxicity by Targeting the Prenylated Prenylome in Myeloid Leukemia Cells

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

DNA damage-induced Leukaemic Stem and Progenitor Cell Kill with Mylotarg and Tipifarnib/Zarnestra Drug Combination In Acute Myeloid Leukemia (AML)

BMS-214662 Eliminates Quiescent and Proliferating Acute Myeloid Leukemia Cells through Activation of Protein Kinase Cβ and Enhances the Efficacy of Cytosine Arabinoside

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Increase of Sensitivity to Chemotherapy and NK-Mediated Cytotoxicity of Leukemic Stem Cell by a Farnesyltransferase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only